MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. reduced its position in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 3.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 492,765 shares of the biopharmaceutical company’s stock after selling 17,740 shares during the period. Charles Schwab Investment Management Inc. owned 0.79% of MacroGenics worth $1,621,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in MacroGenics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 4,707 shares during the period. SG Americas Securities LLC acquired a new position in MacroGenics in the 3rd quarter valued at about $55,000. DRW Securities LLC acquired a new position in MacroGenics in the 2nd quarter valued at about $56,000. XML Financial LLC boosted its position in MacroGenics by 66.0% in the 3rd quarter. XML Financial LLC now owns 17,600 shares of the biopharmaceutical company’s stock valued at $58,000 after buying an additional 7,000 shares during the period. Finally, K2 Principal Fund L.P. purchased a new stake in MacroGenics during the 2nd quarter worth about $63,000. 96.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on MGNX shares. Evercore ISI raised MacroGenics to a “strong-buy” rating in a research report on Monday, September 16th. JMP Securities cut shares of MacroGenics from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. StockNews.com raised MacroGenics from a “sell” rating to a “buy” rating in a research note on Sunday, November 10th. Finally, HC Wainwright restated a “neutral” rating and issued a $4.00 price objective on shares of MacroGenics in a research report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.63.

MacroGenics Price Performance

MacroGenics stock opened at $3.23 on Tuesday. The company has a market capitalization of $202.72 million, a price-to-earnings ratio of -2.04 and a beta of 2.04. The firm’s fifty day moving average price is $3.68 and its 200 day moving average price is $3.89. MacroGenics, Inc. has a 12-month low of $2.95 and a 12-month high of $21.88.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.